Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Decitabine and Tetrahydrouridine in Pulmonary Metastasectomy
NCT02839694Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jul 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of decitabine in cancer (3 cohorts), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Toxicities at 30 days. Planned start Jul 2016; status: withdrawn.
02
Drugs
decitabine
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02839694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02839694.